NutriMedical   Register     Sign-In     View Cart 
  Dr. Bill Deagle, M.D.NewsPRODUCTSWellness ConditionsContact UsHome   Phone Orders 888-212-8871  
Products & News Search:  

  Products / Product Details

< Back to Product Listing

DR BILL'S PRODUCTS: NUTRIMEDS
name how sold price
IBS-CARE 90 tablets 333 mg $39.95
$37.15
Download Product Sheet
Common Uses: Colon-Release Propionyl-L-Carnitine for Inflammatory Bowel Disease
Fourteen patients (aged 16–80 years; mean, 49 years) with mild-to-moderate ulcerative colitis (n = 10) or Crohn's disease colitis with no known small-intestinal Crohn's disease (n = 4), who were receiving stable therapy with oral aminosalicylates, mercaptopurine, or azathioprine for at least 8 weeks were treated with 1 g of orally administered colon-release propionyl-L-carnitine hydrochloride twice a day (1 hour before breakfast and 1 hour before dinner) for 4 weeks. Colonoscopy was performed before and immediately after the treatment period. Clinical response was defined as a decrease of at least 3 points in Disease Activity Index (DAI), and clinical remission was defined as a DAI score of 2 or less. Histological response was defined as an improvement of the histological index by at least 1 point. Seventy-one percent of the patients achieved clinical response (6 of 10 with ulcerative colitis and 4 of 4 with Crohn's disease), and 64% achieved clinical remission (6 of 10 with ulcerative colitis and 3 of 4 with Crohn's disease). Seventy-nine percent of the patients had a histological response; no patient showed histological worsening. The median DAI score improved by 71%. No side effects were reported.

Comment: In a previous double-blind trial, colon-release propionyl-L-carnitine significantly increased the number of responders in patients with mild-to-moderate ulcerative colitis (72% vs. 50%; p = 0.02). The results of the new study confirm the efficacy of this treatment for ulcerative colitis, and suggest that it may also be effective for Crohn's disease of the colon. Propionyl-L-carnitine presumably works by increasing mitochondrial energy production, which appears to be impaired in people with inflammatory colitis.

Merra G et al. Propionyl-L-carnitine hydrochloride for treatment of mild to moderate colonic inflammatory bowel diseases. World J Gastroenterol. 2012;18:5065–5071.
Instructions/How to Use:

Take one tablet before meals to normalize bowel peristalsis activity in IBS and colitis. 

Ingredients:

Liposomal Propionyl-L-Carnitine 333 mg per tablet



 
Product Specials


   VITAMINERALMAX  SALE + FREE SHIPPING!
120 caps
$34.95
$32.50



 QRMA DEVICE + FREE Consults* & Wellness Analysis + FREE Shipping
QRMA Wellness Analysis + NutriMeds Consult
$1,599.95
$1,199.96



ALLERGONE 15%OFF + FREE SHIPPING!
60 caps bottle
$89.95
$62.96



KARDIOVASC CAPS  FREE SHIPPING
180 caps 2 + months
$69.95
$65.05



Additional Links

RADCast Radiation Articles and Daily Reports

ORAL SYSTEM BIOLOGY DR FARRAND ROBSON DDS TMJ OBSTRUCTIVE SLEEP APNEA

International Advocates for Health Freedom -- THE REAL FIGHTERS AGAINST WEAPONIZATION OF FOOD AND ELIMINATION OF NUTRACEUTICAL WELLNESS ACCESS

NO CODEX GENOCIDE! DEFEND DSHEA BY DEFENDING AMERICA FROM ITS PLANNED DESTRUCTION- DEFEND HEALTH FREEDOM GLOBALLY BY OPPOSING GLOBALIZATION

Mobile Phone Radiation: Is it safe or not? Part 1:15 YouTuvbe Video

Association of Prolife Physicians

Shocking True Story US MARINE IN RENAL FAILURE AFTER SECRET VACCINE - GUINEA PIGS WITHOUT CONSENT

Blueprint for influenza pandemic

"We Become Silent - The Last Days Of Health Freedom The Codex-CAFTA Documentary" (2006) A 28-minute video by Kevin Miller

2003-2017 NutriMedical, Inc. All Rights Reserved.   Terms of Use   |   Privacy Policy   |   Site Map